BPC July 07 update

​Biohaven BHVN shares rally on revenue beat +14%; Evaxion EVAX data due pre-market Thursday

Price and Volume Movers

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced preliminary net product revenue of NURTEC ODT (rimegepant) for the second quarter of 2021 of $93 million, well above consensus estimates of $50-55 million. NURTEC ODT is marketed for both acute and preventative migraine. Shares closed up 14% to $112.25.

Daré Bioscience, Inc. (NASDAQ:DARE) shares closed up 24% to $1.88 following a SEC filing which noted the Bill & Melinda Gates Foundation awarded a new grant of up to $48.95 million to support the development of DARE-LARC1, its investigational user-controlled, long-acting reversible contraceptive. An initial payment of $11.45 million will be received this month.

Evaxion Biotech A/S (NASDAQ: EVAX) announced that it will hold a conference call to discuss Phase 1/2a oncology data of EVX-01 and EVX-02 on Thursday, July 8, 2021.

OncoSec Medical Incorporated (NASDAQ:ONCS) shares closed up 22% to $3.40 on news released late-Tuesday of a collaboration with Merck to evaluate TAVO (tavokinogene telseplasmid) with Merck's KEYTRUDA (pembrolizumab), in a Phase 3 randomized clinical trial in patients with metastatic melanoma who are refractory to immune checkpoint therapy.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) shares fell 20% to $18.11 after announcing also late-Tuesday that it intends to offer $80 million of shares of its common stock in an underwritten public offering.

-

Other major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Opiant Pharmaceuticals, Inc. (OPNT): $16.12; +21%.

Virpax Pharmaceuticals, Inc. (VRPX): $5.18; +14%.

IVERIC bio, Inc. (ISEE): $9.61; +12%.

Rain Therapeutics Inc. (RAIN): $18.15; +10%.

ARCA biopharma, Inc. (ABIO): $3.74; +9%.

DECLINERS:

Cleveland BioLabs, Inc. (CBLI): $5.06; -19%.

Tempest Therapeutics Inc. (TPST): $10.93; -17%.

Eloxx Pharmaceuticals, Inc. (ELOX): $1.60; -17%.

Soligenix, Inc. (SNGX): $1.10; -16%.

Novavax, Inc. (NVAX): $185.78; -14%.

Pipeline updates below:

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

CTXR – Citius Pharmaceuticals Inc.
Mino-Lok
Catheter related blood stream infection

$2.08
0.00  0%
Phase 3 Phase 3 trial to be completed by the end of 2021 or early 2022.
$303.6 million

EVAX – Evaxion Biotech A/S
EVX-01 and KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab)
Melanoma/NSCLC/Bladder cancer

$8.58
+0.48  +6%
Phase 2b Phase 1/2 data released July 8, 2021. Objective Response Rate (ORR) of 67%. 22% Complete Response (CR) and 44% Partial Response (PR). Phase 2b trial to be initiated December 2021.
$164.7 million

EVAX – Evaxion Biotech A/S
EVX-02
Adjuvant melanoma

$8.58
+0.48  +6%
Phase 1/2 Phase 2 trial to be initiated 2Q 2022.
$164.7 million

MRNA – Moderna Inc.
mRNA-1010
Flu vaccine

$430.05
-10.60  -2%
Phase 1/2 Phase 1/2 trial initiation announced July 7, 2021. Phase 1/2 trial fully enrolled September 9, 2021.
$173.6 billion

NGM – NGM Biopharmaceuticals Inc.
NGM707 and KEYTRUDA (pembrolizumab)
Solid Tumors

$23.03
-0.81  -3%
Phase 1 Phase 1 trial initiation announced July 7, 2021.
$1.8 billion

TRVN – Trevena Inc.
OLINVYK (oliceridine)
Obesity

$1.36
+0.14  +11%
Phase 1 Phase 1 initiation announced July 7, 2021. Top-line data due YE 2021.
$223.7 million

XENE – Xenon Pharmaceuticals Inc.
XEN1101 (X-TOLE)
Adult Focal Epilepsy

$17.86
+0.86  +5%
Phase 2 Phase 2b completion of enrollment announced July 7, 2021. Top-line data due late-September to mid-October 2021.
$734.5 million